



"Hybrid Closed-Loop" (Artificial Pancreas)

A Metabolic 3D Healthcare System for Diabetes

# MINITZ "Wearable Smart Armband"

Redefining Personalized Healthcare Innovation

### <u>Diabetics Management Problems = Medixbot Features</u>





One Plug & Play Device beat them ALL

MEDIX BOT

2

3

- DIY Separate Devices & Applicators
- 2 One-Time Use All goes to Waste!
- 3 Too Expensive & Not Affordable
- Requires Physical & Digital Connections

All Reusable! with a few Replaceable

Half Price!! Affordable with the same Quality


Personalized & Works Offline (At-edge AI)


### Solution: Medixbot - Closed-Loop Metabolic 3D Healthcare

### 1 Connected Mobile App:



**Workout program** 





### 2 Hybrid Closed-Loop:

- CGM: Continuous Glucose Monitoring
- Auto-Insulin Pump
- NoType.Al Insulin Auto-delivery

### 3 3D Cloud Al System:

- Healthcare Backend
- AI SAAS System
- Big Data

### Medixbot MONO'1 - Personalized Wearable Hybrid Closed-Loop System

Full-stack Integrated Wearable Closed-loop System (IWCS) based on mini-invasive microneedle platform for In-Situ Diabetic monitoring and treatment.

World's 1st to integrates five essential components:

- 1. Continuous Glucose Monitoring (CGM)
- Continuous Blood Monitoring (CBM): Tracks nutrition molecules and carbohydrates
- 3. Automated Insulin Delivery (AID)
- 4. **Embedded At-Edge AI**: intelligent decision-making based on personalized data and historical patterns.
- 5. **Mobile App**: personalized metabolic healthcare, diet plans, exercise routines, telemedicine, etc.




Experience the future of diabetes management

Join the healthcare revolution today!


### Medixbot MONO'2 - Redefining Healthcare Innovation

- Revolutionizing Healthcare with Medixbot Mono-2
  - **Cutting-edge wearable:** Mono-2 redefines healthcare tech, outpacing smartwatches and devices.
  - Innovative Microneedle Arrays: Four arrays, precision drug delivery to data collection.
  - Hygienic Cannula System: Swift rotation, optimal performance, minimal contamination.
  - Pemini Al Network: Cloud and on-device Al, personalized insights, limitless possibilities.
  - **Intuitive User Interface:** Touchscreen control for real-time data, seamless interaction.
  - No-Code Development: Customize on-device, mobile apps, accelerate innovation.
  - Endless Applications: Medical research to biosensors, unlocking boundless innovation.





### Market Size for MONO'1:





### **Market In Numbers:**

- Abbott Laboratories & Dexcom are the leaders in the CGM market, which hit \$5.1 billion in revenue in 2021. Projected \$13.2 billion by 2028. (Ref)
- The Global Insulin Pump Market is valued at USD 4.20 billion in 2021. Projected USD 10.18 billion by 2028 at a CAGR of 15.90%. (Ref)
- "Smart health watches global market was USD 59.02 billion in 2021, would rocket up to USD 185.63 billion by 2029 with a CAGR of 15.40%/year.

## Market Size for MONO'2:

### Our Target Market:

# \$1 Billion

#### Attractive Opportunities in the Wearable Healthcare Devices Market



North America accounted for the largest share of the wearable healthcare devices market in 2020. The increasing awareness of fitness, lifestyle, and home healthcare and growing investments, funds, and grants are the key factors driving market growth in this regional segment.



16.2 USD Billion

30.1 USD Billion

13.2%

The wearable healthcare devices market is projected to reach USD 30.1 billion by 2026 from USD 16.2 billion in 2021, at a CAGR of 13.2%.



The robust penetration of 3G and 4G networks for uninterrupted healthcare services and development of technologically advanced products are driving the wearable healthcare devices market



The outbreak of COVID-19 has led to an increase awareness for fitness and healthy lifestyle in many countries. This is expected to support the growth of the wearable healthcare devices market.



Acquisitions, collaborations, partnerships, agreements, and product launches & approvals were the most widely adopted growth strategies by market players.



Emerging markets are expected to offer lucrative growth opportunities for players in the market during the forecast period.

# **Projections**

\*\*\* Two LOIs from the Ministry of Health in Turkey and Iraq.



\*\*\* 20% tax subsidy
- CE Mark




**Expanding to North American markets:** 

- FDA Approval








#### THE TEAM



- MSc in Al and BSc in CS
- 30+ years of Tech/Biz experiences
- Plan-Do-Check-Act cycle of Kaizen (Imai, Masaaki), and
   Lazim's Aqile-Leader(Multi-Personas))

- Cofounder of 4 Startups
  - SAASPASS (exit)
  - o Crealnno (exit)
  - o Solidpass (Security keys)
  - o Aradiom Telekom
- Mentor, Invest & Run Venture Studio in East Europe









Prof.Dr. Mustafa Zahid YILDIZ
Electronics Eng., SUBU.
Electronics/Biomed Advisor



Ahmet Turan TALAS, Specialist Project Scientific CleanRoom Tech. Coordinator



Furkan Öztürk, Mechatronic Engineer, Medixbot



**Prof.Dr. Mustafa Can**Biomed and chemical Eng., Univ.,
Sakarva Biomed Advisor



James Nyamhondoro, MD Healthcare Advisor, Chronic Diseases expert




Sami Hamdan Al-Saedi, MD Medical Devices Advisor, BSc. Medicine

# Thanks for your support!



#### **MEDIXBOT**

The Deep Biotech Company



medixbot.com





**L** +1 332-207-5932

ali@cr34.com

#### follow us on



YouTube



https://www.youtube.com/@alilazim7630



twitter



https://twitter.com/medixbot



twitter



https://twitter.com/alilazim



LinkedIn



https://www.linkedin.com/in/ali-lazim-510b156/